NanoViricides Reports HIVCide-I May Be Functional Cure for HIV/AIDS
Today NanoViricides Inc. (more
NNVC Charts)
reported that HIVCide-I was significantly superior to the Current Anti-HIV Three
Drug Cocktail currently used to treat HIV/AIDS. HIVCide-I may be a "functional
cure cure for HIV/AIDS."

NanoViricides Inc has a market capitalization (at $1.33) of $
158 million assuming 119 million shares
outstanding.
My dream is a big American drug company like Johnson &
Johnson (JNJ), Pfizer (
PFE) or Merck
(MRK) buys NNVC for maybe $5 billion. I would even be happy to have the
technology leave the US if a big foreign company like Bayer, GlazoSmithKline
(GSK), Novartis (NVS), Sanofi-Aventis (SAN), Hoffmann–La Roche (SWX Europe:
ROG) or AstraZeneca (AZN) paid
more.
Press Release
from NanoViricides, Inc.
NanoViricides, Inc. Reports that
HIVCide-I Was Significantly Superior to the Current Anti-HIV Three Drug Cocktail
Standard
The Novel Mechanism of
Action of HIVCide-I Defines a New Class of Anti-HIV Drugs
WEST
HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB),
(the “Company”) said that additional biological
tests and data analysis have shown that animals treated with its lead anti-HIV
drug candidate, HIVCide™-I, demonstrated a substantially greater reduction in
viral load -- number of infectious virus particles per milliliter of blood --
when compared to the animals given the anti-HIV “combo cocktail” in a
preliminary animal study. An important objective of anti-HIV treatment is
to minimize the viral load.
These new data expand on the findings
previously reported and are consistent with earlier results.
Related Stories
The above story is the opinion of the author only and it does not reflect
iStockAnalyst opinion. Further, the author is not personally advising you
regarding the suitability of the story for your investment needs. In no event
iStockAnalyst will be liable for any loss or damage including without
limitation, indirect or consequential loss or damage, or any loss or damage
whatsoever arising from or arising out of, or in connection with the use of this
information. Please consult your investment advisor before making any investment
decision.